Health & Environmental Research Online (HERO)


Print Feedback Export to File
7064854 
Journal Article 
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer 
Liu, K; Jiang, G; Zhang, A; Li, Z; Jia, J; , 
2020 
Yes 
BMC Cancer
ISSN: 1471-2407
EISSN: 14712407 
BMC 
LONDON 
English 
32000711 
WOS:000520409000001 
The prognosis of non-small-cell lung cancer (NSCLC) with brain metastases is very poor. Currently, therapeutic methods for this patient population include whole-brain radiation therapy (WBRT), surgery, radiosurgery and systemic treatment. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) could be effective on cerebral metastases of mutated NSCLC. However, which EGFR-TKIs is more appropriate is still unknown.